Shares of IsoRay, Inc. ISR are up sharply on Monday amid a positive report of its Cesium-131 therapy.
The company announced that its Cesium-131 therapy stopped brain cancers from recurring in treated locations where previous conventional treatments failed.
From the report:
“According to Dr. Dardis’ presentation, the patients who were treated with the new approach using Cesium-131 fared better than they had using earlier, conventional treatment. In fact, 26 of the 27 patients (96%) had not experienced a recurrence of the treated cancer within the treated bed during the follow-up period.”
Shares of IsoRay were up 21 percent at $1.96.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.